Cero Therapeutics Holdings, Stock Investor Sentiment
| CERO Stock | 0.06 0.01 19.00% |
About 61% of CERo Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding CERo Therapeutics Holdings, suggests that many traders are alarmed. CERo Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in CERo Therapeutics Holdings,. Many technical investors use CERo Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
CERo |
Far too much social signal, news, headlines, and media speculation about CERo Therapeutics that are available to investors today. That information is available publicly through CERo media outlets and privately through word of mouth or via CERo internal channels. However, regardless of the origin, that massive amount of CERo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CERo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CERo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CERo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CERo Therapeutics alpha.
CERo Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | CERo Therapeutics says CEO Atwood, CFO Carter to step down | 09/25/2024 |
2 | Short Interest in CERo Therapeutics Holdings, Inc. Declines By 59.1 | 09/27/2024 |
3 | Disposition of 1317956 shares by Brian Atwood of CERo Therapeutics at 1.77 subject to Rule 16b-3 | 09/30/2024 |
4 | Insider Trading | 10/01/2024 |
5 | CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer | 10/02/2024 |
6 | CERo Therapeutics, Inc. Provides Corporate Update | 10/21/2024 |
7 | CERo Therapeutics Stock Is Soaring Monday Whats Going On | 11/11/2024 |
8 | Nasdaq Tumbles Over 200 Points Alibaba Posts Upbeat Sales | 11/15/2024 |
9 | Cero therapeutics investor Sloan Stuart sells 55,538 in stock | 11/20/2024 |
10 | Acquisition by Patel Shami of 127500 shares of CERo Therapeutics at 0.0951 subject to Rule 16b-3 | 12/02/2024 |
11 | Disposition of 1236874 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.12 subject to Rule 16b-3 | 12/06/2024 |
12 | Disposition of 850543 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.11 subject to Rule 16b-3 | 12/09/2024 |
13 | Disposition of 1570947 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.09 subject to Rule 16b-3 | 12/10/2024 |
14 | Cero Therapeutics sees 383,369 in stock sales by YK Bioventures | 12/11/2024 |
Check out CERo Therapeutics Hype Analysis, CERo Therapeutics Correlation and CERo Therapeutics Performance. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.45) |
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.